Canine Flu Therapeutics Market Outlook (2023 to 2033)

The canine flu therapeutics market is anticipated to flourish at an average CAGR of 4.1% between 2023 and 2033. The market is expected to hold a market share of US$ 3.06 billion by 2033, while the market is likely to reach a value of US$ 2.04 billion in 2023.

Canine flu is segmented into two types, they are H3N8 viruses and H3N2 (Seasonal influenza A) viruses.

Attributes Details
Canine Flu Therapeutics Market CAGR (2023 to 2033) 4.1%
Canine Flu Therapeutics Market Size (2023) US$ 2.04 billion
Canine Flu Therapeutics Market Size (2033) US$ 3.06 billion

Almost all dogs are susceptible to canine flu with direct contact or with respiratory discharges from infected dogs. The symptoms of illness are eye discharges, upper respiratory illness, reduced appetite, runny nose, cough, fever, and lethargy.

Moreover, the severity of canine flu ranges from no symptoms to terminal illness, resulting in pneumonia and sometimes death. Therefore, the canine flu therapeutics market is likely to have significant growth during the forecast period and more adoption by dog owners to reduce the spread of flu and infections.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Demand Drivers Affecting the Growth of the Canine Flu Therapeutics Market

Several factors have been identified by the experts of FMI while analyzing the canine flu therapeutics in depth that are propelling the market growth at a moderate pace. They are as follows:

Attribute Details
Rising Diseases A robust increase in the incidences of diseases with no specific treatment is likely to boost the canine flu therapeutics market expansion.
Innovation The innovators in the market are getting the advantage of a monopolistic market as there is less competition across the globe.
Government Support Increasing government support and rising research and development activities by manufacturers are likely to foster the growth of the canine flu therapeutics market in the coming years.
Cost-effectiveness Rapid turnaround time and lower procedure cost than conventional methods fuel the demand for canine flu therapeutics in the canine influenza treatment market.

Factors Deterring the Market Expansion of Canine Flue Therapeutics

Although key demand drivers have been identified in the canine flu therapeutics market, it is also witnessed that certain aspects are likely to hinder growth and further slow down the pace of expansion for the concerned market. The curbing factors are as follows.

Attribute Details
Lack of expertise Lack of awareness and absence of trained professionals in developing and underdeveloped economies may impede the propulsion of the canine flu therapeutics market.
Vaccine Limitations The global market for canine flu therapeutics is expected to be deterred by a limited number of vaccines available.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Country-wise Insights

Countries Revenue Share % (2022)
United States 34.6%
Germany 5.6%
Japan 5.3%
North America 37.6%
Europe 25.3%
Countries CAGR % (2023 to 2033)
China 4.2%
India 3.4%
United Kingdom 2.4%
Australia 3.0%

How is the North America Canine Flue Therapeutics Market Performing?

North America is projected to hold the highest market share of canine flu therapeutics and is anticipated to dominate the market during the forecast period. The North American region held 37.6% of the market share for canine flu therapeutics in 2022.

The market size in North America is expanding owing to factors like:

  • Rising infection rates have been recorded in pet dogs in North America.
  • Increased awareness of the disease and its treatment with diagnostic methods further bolstering the demand for canine flu therapeutics in this region.

Growth Outlook of Europe Canine Flu Therapeutics Market

Europe is anticipated to hold the second-leading share in the global canine flue therapeutics market and has substantial growth over the forecast period. At present, the European region accounts for 25.3% of the total market share of canine flu therapeutics.

The marker size expansion in Europe can be attributed to the following factors:

  • Increasing animal adoption and rising consumer spending on veterinarian services due to the rise of disposable income in the European regions is driving the growth of the canine flu market.
  • The technological advancement in the healthcare sector in the region and expanding veterinary healthcare infrastructure are expected to augment the canine flu therapeutics market.

Categorical Analysis

Category Drug Class
Leading Segment NSAIDs
Market Share (2022) 57.8%
Category Distribution Channel
Leading Segment Veterinary Clinics
Market Share (2022) 44.8%

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Start-up Ecosystem

New Entrants Ardently Performing in the Canine Flu Therapeutics Market

According to the research study conducted by FMI, the new entrants in the canine flu therapeutics market continually indulge in several collaborations and highly invest in research and development activities to provide more effective therapeutic solutions to dog owners, which would cure influenza faster and reduce the spread.

Zoetis is a start-up company lining up rival vaccines to fight a new strain of dog flu. The new vaccines don't protect against the previously known strain of dog flu, even though that illness is still circulating. So, dog owners who want total protection must get separate vaccines for H3N8 and H3N2.

Schering-Plough Animal Health is an innovation-driven, science-centered global healthcare company. Schering-Plough creates therapies that help save and improve lives worldwide through biopharmaceutical research and collaborations with partners. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products and is likely to impact the therapeutics market in the coming years.

Some other start-ups increasing in the market are Wiggles, Fidocure, Itch, Nexvet, Hesterbiosciences, and Gallant.

Competitive Analysis

Market Players to Fuel Further Growth in the Canine Flu Therapeutics Market

The market is highly competitive due to the presence of several participants. The key players are adopting several growth strategies, and finding means to upgrade the vaccines that can cure influenza in animals faster and more cost-effectively.

Recent Developments

  • In August 2021, Merck Animal Health announced a new name for its cattle vaccine portfolio, one of the industry's prominent and most comprehensive vaccine portfolios. The goal of the new naming and packaging is to make it easier for customers to recognize the company's vaccines and to identify specific formulations.
  • In November 2020, Merck announced it had received a conditional license from the USDA to market Canine Influenza Vaccine H3N2- just one week after Zoetis received the same USDA nod for its vaccine. Both new vaccines require two doses, administered a few weeks apart.
  • In October 2018, the European Clinical Office was approved to utilize serological hemagglutination hindrance (HI) for flu testing.
  • Boehringer Ingelheim International GmbH has decided to expand veterinary vaccine capacity for rising transboundary diseases in France.

Key Players

  • Interver Inc
  • Merck Animal Health
  • al Health
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Pfizer Inc.
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.

Key Segments Covered

By Drug Class:

  • Antibiotics
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Antiviral Drugs

By Distribution Channel:

  • Veterinary Clinics
  • Veterinary Pharmacies
  • Online Pharmacies

Key Regions Covered:

  • North America
    • United States
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Japan
  • Asia Pacific Excluding Japan
    • China
    • India
    • Malaysia
    • Singapore
    • Australia
    • Rest of Asia Pacific Excluding Japan (APEJ)
  • The Middle East and Africa
    • GCC Countries
    • Israel
    • South Africa
    • Middle East and Africa (MEA

Frequently Asked Questions

Which countries dominate the global Canine Flu Therapeutics Market?

The United States, Japan, and China dominate the global Canine Flu Therapeutics market.

What is the growth forecast for the Canine Flu Therapeutics market?

The Canine Flu Therapeutics market is forecast to register a CAGR of 4.1% through 2033.

How is the historical performance of the market?

From 2018 to 2022, the market grew at a CAGR of 4%

Which is the top trend in the Canine Flu Therapeutics market?

Technological advancement disrupts the current market trends, such as the development of new vaccines and antiviral drugs.

What is the projected size of the market by 2033?

The global market size of Canine Flu Therapeutics to reach US$ 2.04 billion by 2033.

Table of Content

1. Executive Summarysss

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Antibiotics

        5.3.2. Nonsteroidal anti-inflammatory Drugs (NSAIDs)

        5.3.3. Antiviral Drugs

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        6.3.1. Veterinary Clinics

        6.3.2. Veterinary Pharmacies

        6.3.3. Online Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Class

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Class

        14.2.3. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Class

            15.1.2.2. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Class

            15.2.2.2. By Distribution Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Class

            15.3.2.2. By Distribution Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Class

            15.4.2.2. By Distribution Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Class

            15.5.2.2. By Distribution Channel

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Class

            15.6.2.2. By Distribution Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Class

            15.7.2.2. By Distribution Channel

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Class

            15.8.2.2. By Distribution Channel

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Class

            15.9.2.2. By Distribution Channel

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Class

            15.10.2.2. By Distribution Channel

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Class

            15.11.2.2. By Distribution Channel

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Class

            15.12.2.2. By Distribution Channel

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Class

            15.13.2.2. By Distribution Channel

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Class

            15.14.2.2. By Distribution Channel

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Class

            15.15.2.2. By Distribution Channel

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Class

            15.16.2.2. By Distribution Channel

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Class

            15.17.2.2. By Distribution Channel

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Class

            15.18.2.2. By Distribution Channel

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Class

            15.19.2.2. By Distribution Channel

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Class

            15.20.2.2. By Distribution Channel

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Drug Class

            15.21.2.2. By Distribution Channel

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Drug Class

            15.22.2.2. By Distribution Channel

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Drug Class

            15.23.2.2. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Interver Inc

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Merck Animal Health

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. al Health

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. GlaxoSmithKline Plc.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Novartis AG

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Bristol-Myers Squibb Company

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Eli Lilly and Company

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Pfizer Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Boehringer Ingelheim International GmbH

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Sanofi

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Abbott Laboratories

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. F. Hoffmann-La Roche Ltd.

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Canine Arthritis Treatment Market

October 2019

REP-GB-3552

February 2024

333 pages

Healthcare

Peptide Therapeutics Market

February 2022

REP-GB-1038

January 2023

332 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Canine Flu Therapeutics Market